Vitiligo (Dermatology) - Drugs In Development, 2021
- $ 2000
- April 2024
- 203 pages
Cerdulatinib (PRT-2070, PRT-062070, DMVT-##) is under development for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, B-cell non- Hodgkin lymphoma (NHL) (including diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma and mantle cell lymphoma), arthritis, cutaneous T- cell lymphoma, Waldenstrom's macroglobulinemia, atopic dermatitis, vitiligo, alopecia areata and inflammatory skin diseases, peripheral T-cell lymphoma including angioimmunoblastic T cell lymphoma, follicular T-cell lymphoma, nodal lymphomas of T follicular helper, anaplastic large cell lymphoma, hepatosplenic T-cell lymphoma, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, angioimmunoblastic T cell lymphoma and extranodal NK/T-cell lymphoma. [...] The drug candidate is in Phase IIa stage of development for relapsed or refractory diffuse large B-cell lymphoma and B-cell non-Hodgkin lymphomas including diffuse large B-cell lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma , follicular lymphoma, Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Waldenstrom's macroglobulinemia, B-Cell Chronic Lymphocytic Leukemia and mantle cell lymphoma in the US. It is also in Phase II stage for angioimmunoblastic T-cell lymphoma. [...] It is in Phase I stage of development for angioimmunoblastic T cell lymphoma, follicular T-cell lymphoma, nodal lymphomas of T follicular helper, hepatosplenic T- cell lymphoma, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T- cell lymphoma and extranodal NK/T-cell lymphoma.